Vatelizumab
Vatelizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target integrin alpha-2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | — | 1 |
| Uterine myomectomy | D063186 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | — | — | — | 2 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 2 | — | — | — | 2 |
| Sclerosis | D012598 | — | — | — | 2 | — | — | — | 2 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 2 | — | — | — | 2 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 2 | — | — | — | 2 |
| Ulcer | D014456 | MPATH_579 | — | — | 2 | — | — | — | 2 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vatelizumab |
| INN | vatelizumab |
| Description | Vatelizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743086 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | A4R7G50030 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ITGA2
ITGA2
Organism
Homo sapiens
Gene name
ITGA2
Gene synonyms
CD49B
NCBI Gene ID
Protein name
integrin alpha-2
Protein synonyms
alpha 2 integrin, alpha 2 subunit of VLA-2 receptor, CD49 antigen-like family member B, CD49b, Collagen receptor, glycoprotein Ia, GPIa, human platelet alloantigen 5, human platelet alloantigen system 5, integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor), platelet antigen Br, platelet glycoprotein GPIa, Platelet membrane glycoprotein Ia, very late activation protein 2 receptor, alpha-2 subunit, very late activation receptor alpha-2 subunit, very late activation receptor subunit alpha-2, VLA-2 subunit alpha
Uniprot ID
Mouse ortholog
Itga2 (16398)
integrin alpha-2 (Q6P1C7)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 22 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use